At NxStage we are leading a revolution to transform renal care.
- Based on the most current USRDS reports, 571,414 patients in the U.S. suffered from End Stage Renal Disease (ESRD) in 20091. This represented a 3.8% increase from 2008. Approximately 69% or 394,000 of these U.S. patients received routine dialysis treatments to treat their kidney failure.1
- Moving forward, over 110,000 patients are expected to start dialysis treatment each year in the U.S.1
- Approximately 91% of U.S. patients receive in-center dialysis treatment; approximately 8% do Peritoneal Dialysis (PD) and a little over 1% do more frequent home hemodialysis with the NxStage System One.1
- Mortality rates for in-center dialysis remain at approximately 20%, annually.1
- Recent clinical data from the FREEDOM study and the Chronic Disease Research Group’s study comparing mortality risk in dialy home versus thrice-weekly in-center patients2 support broader adoption of more frequent, home hemodialysis with the NxStage System One. Data from these studies, together with additional objective data from other large, well-designed trials such as the Frequent Hemodialysis Network’s Daily Trial3, have proven that more frequent hemodialysis has a positive impact on quality of life, survival and clinical outcomes.
- The data is consistent, compelling and overwhelmingly positive. It suggests that more patients can and should benefit from NxStage’s life changing therapy, and that these patients may live longer lives.
We’re more inspired than ever.
- We believe innovation, creativity, and passionate commitment can fundamentally change the dialysis treatment paradigm and improve the quality of renal care.
- We strive for clear and simple solutions, avoiding unnecessary complexity.
- We believe that working as a team, we can make a positive difference in the world by creating broad access to our life changing therapy.
- We seek solutions that enhance quality of care and patient quality of life.
- U.S. Renal Data System, USRDS 2011 Annual Data Report.
- Weinhandl, E et al. Relative Mortality in Daily Home and Matched, Thrice-Weekly In-Center Hemodialysis Patients. Abstract Presentation at the 2011 National Kidney Foundation Spring Clinical Meeting.
- The FHN Trial Group. In-center hemodialysis six times per week versus three times per week. New England Journal of Medicine 2010; 363:2287-2300.